Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 30Parkinson Disease 4, Autosomal Dominant Lewy Body 4Neoplasms 4Neoplasm Metastasis 3Prostatic Neoplasms, Castration-Resistant 2Prostate Cancer Metastatic 2Metastatic Hormone Sensitive Prostate Cancer 2Metastatic Castration-resistant Prostate Cancer 2Bulbo-Spinal Atrophy, X-Linked 2mCRPC 1Recurrence 1Prostatic Diseases 1Patient Preference 1Metastatic Castration-resistent Prostate Cancer 1Metastatic Castration-resistant Prostate Cancer (mCRPC) 1Metastatic Castration-Resistant Prostate Cancer 1Metastatic Castration Resistant Prostate Cancer 1MCRPC 1Genital Diseases, Male 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Breast Neoplasms 1Adenocarcinoma 1

Interventions

enzalutamide 2Androgen Antagonists 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Metastatic Hormone Sensitive Prostate Cancer × enzalutamide × Clear all
NCT04076059 2026-04-17

China ARCHES

Astellas Pharma Inc

Phase 3 Active not recruiting
180 enrolled 24 charts
Genitourinary

Metastatic Hormone Sensitive Prostate Cancer

NCT02677896 2025-10-24

ARCHES

Astellas Pharma Inc

Phase 3 Completed
1,150 enrolled 23 charts 1 FDA
Genitourinary

Metastatic Hormone Sensitive Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡